SOL 116
Alternative Names: anti-BSSL; Anti-BSSL antibody - Lipum; Bile salt-stimulated lipase targeting monoclonal antibody - Lipum; SOL-116Latest Information Update: 10 Mar 2025
At a glance
- Originator Lipum
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Sterol esterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Phase I Rheumatoid arthritis
- No development reported Autoimmune disorders
Most Recent Events
- 28 Feb 2025 The efficacy, adverse event, pharmacokinetic and Immunogenicity data from a phase I trial in Rheumatoid arthritis released by Lipum
- 26 Feb 2025 Lipum plans a phase II trial for Rheumatoid arthritis in 1H of 2026
- 28 Nov 2024 Lipum AB completes a phase I trial in Rheumatoid arthritis (In volunteers) in Netherlands (SC, Injection) (NCT05576012)